Session » 4M102 ACR Abstract: Misc Rheum & Inflam DZ I: DADA2, Cardiac Sarcoid,Cancer Immunotherapy(1911–1916)

Date: Monday, October 22, 2018

Time: 4:30PM-6:00PM

Meeting: 2018 ACR/ARHP Annual Meeting

4:30PM-6:00PM: Abstract Number: 1915

Big Data Analysis of Autoimmune Diseases Induced By Cancer Immunotherapies: Identifying Pharmacological Patterns of Organ-Specific Involvement

4:30PM-6:00PM: Abstract Number: 1913

Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis

4:30PM-6:00PM: Abstract Number: 1916

Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy

4:30PM-6:00PM: Abstract Number: 1914

Rheumatic Syndromes Associated with Immune-Checkpoint Inhibitors: A Single-Center Cohort of 61 Patients

4:30PM-6:00PM: Abstract Number: 1911

The Expanding Clinical Spectrum of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)

4:30PM-6:00PM: Abstract Number: 1912

Treatment of Cardiac Sarcoidosis: A Comparative Study of Steroids Alone Versus Steroids Associated with Immunosuppressive Drugs

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].